InterVenn Biosciences, a precision diagnostics company advancing liquid biopsy with glycoproteomics, and Aranscia, a global provider of award-winning clinical workflow and diagnostic technology ...

To improve ovarian cancer screening, researchers led by Johns Hopkins University’s Victor E. Velculescu, MD, PhD, developed a combination liquid biopsy approach. It has three components: measurements ...

A novel artificial intelligence (AI) protocol called DeepHRD was able to predict homologous recombination deficiency (HRD) in ovarian and breast cancers directly from routine histopathological slides.

First women’s health test marks a new chapter for InterVenn, providing access to non-invasive testing that differentiates between cancerous and benign pelvic masses for improved treatment planning ...

Early-stage gynecologic cancer is confined to its original site and often treatable; diagnosis, surgery, and new therapies improve outcomes. Your diagnosis of an early-stage (Stage 1) gynecologic ...

Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. So one of the biggest challenges in ovarian ...

Liquid biopsies analyze materials like circulating tumor DNA (ctDNA) in the blood to provide a non-invasive look at a cancer’s genetic profile. They are highly effective for tracking tumor evolution, ...

To date, the "liquid biopsy," a blood test that detects evidence of cancer in the circulation, has generated a lot of excitement in the lab but little in the clinic. The only liquid biopsy currently ...

Being diagnosed with cancer is one of the scariest things imaginable. But a cancer diagnosis doesn't have to be a death ...